Mass Medical Angels

MA2 does not have a centralized investment committee in the traditional venture-capital sense. Each member evaluates opportunities independently and commits personal capital on a deal-by-deal basis. The group's physician-investor makeup means clinical feasibility assessments often drive individual decisions alongside the group's broader due-diligence processes.

The group's primary sourcing channel is the clinical and academic networks of its physician and life-science executive members, concentrated around Harvard-affiliated hospitals, MIT, and the Boston-area biotech cluster. MA2 also reviews companies emerging from local accelerators, university tech-transfer offices, and referrals from Boston-based healthcare venture funds.

MA2 operates as a member-syndicated angel group, not a pooled fund. Individual accredited-investor members decide whether to participate in each deal and write their own checks. The group facilitates sourcing, diligence coordination, and syndication mechanics, but there is no pooled vehicle with a fixed capital commitment.

The group targets seed and Series A-stage companies across therapeutics, medical devices, diagnostics, and digital health. MA2's clinician-investor base means a meaningful portion of the portfolio has historically consisted of companies where technical or clinical evaluation provides an edge in assessing scientific risk.

The group's primary concentration is the Massachusetts life-sciences corridor, particularly companies with ties to Boston and Cambridge research institutions. MA2 also maintains a presence in Ingelheim, Germany, and Tokyo, Japan, and has invested in European companies when member networks provide sourcing access, but it does not operate dedicated ex-US funds.